MediWound, U.S. Department of Health and Human Services dermatology news
HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded MediWound a contract worth up to $112 million to support development, manufacturing and procurement of NexoBrid. NexoBrid is in U.S. Phase III testing to remove eschar in adults with deep partial and full-thickness thermal burns. The five-year base contract includes $24 million to support development and FDA approval of NexoBrid for use in thermal burn injuries, plus $16 million for procurement of NexoBrid, which is contingent upon FDA emergency use authorization (EUA) and/or FDA marketing authorization for the product. The contract also includes options for up to an additional $22 million to expand NexoBrid’s indications, plus up to $50 million for additional procurement. ...